KaydedilenlerDerginizi ekleyin

Dergiler / BEYOGLU EYE JOURNAL / 2016 / Cilt: 1 - Sayı: 1

Photodynamic Therapy and Bevacizumab Combination for Polypoidal Choroidal Vasculopathy Refractory to Intravitreal Ranibizumab

Zeynep ALKIN
Abdullah ÖZKAYA
Sibel AHMET
Ökkeş BAZ
Mesut TOGAC
İrfan PERENTE
Mühittin TAŞKAPILI
Sayfa
10–14
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

VA improvement may be obtained in limited number of eyes

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objectives: The present study is an evaluation of outcomes of photodynamic therapy (PDT) combined with intravitreal injections of bevacizumab for polypoidal choroidal vasculopathy (PCV) that was nonresponding to ranibizumab injections.
📊
Temel Bulgular & Veri:Methods: This retrospective study included 37 eyes of 37 patients with PCV.
💡
Sonuç & Katkı:VA improvement may be obtained in limited number of eyes
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

Objectives: The present study is an evaluation of outcomes of photodynamic therapy (PDT) combined with intravitreal injections of bevacizumab for polypoidal choroidal vasculopathy (PCV) that was nonresponding to ranibizumab injections. Methods: This retrospective study included 37 eyes of 37 patients with PCV. Principal outcome measurements used were mean change in best corrected visual acuity (BCVA) and central macular thickness (CMT), and regression rate of polypoidal lesions. Results: Mean follow-up time was 11.8±7.2 months. Mean BCVA decreased significantly from 0.69±0.42 logMAR at baseline to 0.78±0.42 logMAR at final visit (p=0.01). BCVA improved in 9 (24.3%) eyes, decreased in 11 (29.7%), and remained stable in 17 (45.9%) eyes. Mean CMT decreased from 352.2 µm (range: 139-573 µm) at baseline to 318±117.1 µm (range: 136–585 µm) at final visit (p=0.26). Seventeen (45.9%) eyes achieved dry macula, defined as absence of intraretinal or subretinal fluid on optical coherence tomography at 6 months. In addition, 25 eyes (67.5%) showed complete regression of polypoidal lesions. Conclusion: PDT combined with bevacizumab may be beneficial in resolution of exudation in eyes refractory to ranibizumab injections. VA improvement may be obtained in limited number of eyes

🔖

Bu Makaleye Atıf Yap

ALKIN, Z., ÖZKAYA, A., AHMET, S., BAZ, Ö., TOGAC, M., PERENTE, İ., TAŞKAPILI, M. (2016). Photodynamic Therapy and Bevacizumab Combination for Polypoidal Choroidal Vasculopathy Refractory to Intravitreal Ranibizumab. BEYOGLU EYE JOURNAL, Cilt: 1 - Sayı: 1, 10–14. https://ajindex.com/articles/150099

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (15)

  1. Yannuzzi LA, Sorenson J, Spaide RF, Lipson B. Idiopathic polypoidal choroidal vasculopathy (IPCV). Retina 1990;10:1–8
  2. Spaide RF, Yannuzzi LA, Slakter JS, Sorenson J, Orlach DA. Indocyanine green videoangiography of idiopathic polypoidal choroidal vasculopathy. Retina 1995;15:100–10
  3. Lim LS, Mitchell P, Seddon JM, Holz FG, Wong TY. Age-related macular degeneration. Lancet 2012;379:1728–38
  4. Stangos AN, Gandhi JS, Nair-Sahni J, Heimann H, Pournaras CJ, Harding SP. Polypoidal choroidal vasculopathy masquerading as neovascular age-related macular degeneration refractory to ranibizumab. Am J Ophthalmol 2010;150:666–73
  5. De Salvo G, Vaz-Pereira S, Keane PA, Tufail A, Liew G. Sensitivity and specificity of spectral-domain optical coherence tomography in detecting idiopathic polypoidal choroidal vasculopathy. Am J Ophthalmol 2014;158:1228–38
  6. Laude A, Cackett PD, Vithana EN, Yeo IY, Wong D, Koh AH, et al. Polypoidal choroidal vasculopathy and neovascular age-related macular degeneration: same or different disease? Prog Retin Eye Res 2010;29:19–29
  7. Gomi F, Tano Y. Polypoidal choroidal vasculopathy and treatments. Curr Opin Ophthalmol 2008;19:208–12
  8. Cho M, Barbazetto IA, Freund KB. Refractory neovascular age-related macular degeneration secondary to polypoidal choroidal vasculopathy. Am J Ophthalmol 2009;148:70–8
  9. Cheng CK, Peng CH, Chang CK, Hu CC, Chen LJ. One-year outcomes of intravitreal bevacizumab (avastin) therapy for polypoidal choroidal vasculopathy. Retina 2011;31:846–56
  10. Gomi F, Sawa M, Sakaguchi H, Tsujikawa M, Oshima Y, Kamei M, et al. Efficacy of intravitreal bevacizumab for polypoidal choroidal vasculopathy. Br J Ophthalmol 2008;92:70–3
  11. Kokame GT, Yeung L, Lai JC. Continuous anti-VEGF treatment with ranibizumab for polypoidal choroidal vasculopathy: 6-month results. Br J Ophthalmol 2010;94:297–301
  12. Lai TY, Chan WM, Liu DT, Luk FO, Lam DS. Intravitreal bevacizumab (Avastin) with or without photodynamic therapy for the treatment of polypoidal choroidal vasculopathy. Br J Ophthalmol 2008;92:661–6
  13. Kokame GT, Yeung L, Teramoto K, Lai JC, Wee R. Polypoidal choroidal vasculopathy exudation and hemorrhage: results of monthly ranibizumab therapy at one year. Ophthalmologica 2014;231:94–102
  14. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432–44
  15. Rosenfeld PJ, Brown DM, Heier JS, Boyer